Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon

Fig. 4

Average treatment-time with glatiramer acetate (GA) according to patient’s treatment persistence group. Graph showing average treatment-time (ATT) in months (±standard deviation) with glatiramer acetate (GA) at the Neuroimmunology and MS Unit of La Paz University Hospital between January 2004 and October 2013, according to patient’s GA treatment persistence category

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us